Kornimate/medical-research-clean huggingface dataset:
race, ethnicity, socioeconomic status and prolapse-related decisional conflict

Conditions: Pelvic Organ Prolapse; Prolapse, Urogenital

Summary: this study is trying to see if people from different backgrounds have different feelings when making treatment decisions about prolapse.

this multi-center study will include patients ages \>18 years with prolapse symptoms who have new patient consultations to female pelvic medicine and reconstructive surgery providers. after the new-patient consultation, patients will be contacted to see if they are interested in the study. if so, informed consent will be obtained before they complete a 1 page questionnaire that assesses their eligibility for participation. the questionnaires are: decisional conflict scale; pelvic floor disorders autonomy preference index; control preferences scale; pelvic floor distress inventory (pfdi 20); satisfaction with decision scale for pelvic floor disorders; impression questionnaire. patients will self-identify their zip-code on the patient impression questionnaire. this will enable a geographic analysis that will assess the relationships of neighborhood and commute on decision making. for the purposes of this study, patients will self-identify their demographic information. urm patients will be those who self-identify as having a non-caucasian race and/or a hispanic ethnicity. providers seeing patients that are included in this study will also be consented prior to completing a 1 time demographics questionnaire. additional clinical data will also be obtained. patients will be able to utilize interpreters to participate. information regarding the use of interpreters will be collected. questionnaires that are available in, and validated in, non-english languages will be used as appropriate. the lead study site is women \& infants hospital/ brown university, with additional study sites planning to participate in the study.

Eligibility criteria:
inclusion criteria: * provider inclusion criteria consists of fpmrs providers at study sites seeing new patients with symptoms of pelvic organ prolapse. patient inclusion criteria consists of new patients 18 years or older with symptoms of pelvic organ prolapse. exclusion criteria: * provider exclusion criteria consists of providers who decline participation. patient exclusion criteria consists of patients who decline participation, and those who cannot complete the study interventions with the assistance of an interpreter.

Keywords: decisional conflict pelvic organ prolapse decision making
a study of pattern of presentation of pulmonary tuberculosis patients undergoing treatment at assiut university hospital

Conditions: Pulmonary Tuberculosis

Summary: the objective of the investigator's study is to detect the characteristics, pattern and outcome of pulmonary tuberculosis patients treated at assiut university hospital by collecting their demographic, clinical, laboratory and radiological data.

tuberculosis (tb) is a problem of global importance, it is a medical, social and economic disaster of immense magnitude that is occurring over the world tb remains one of the major health risks associated with morbidity and mortality. worldwide, about 10 million tb cases have been reported in 2017, and about 1.57 million cases have died the estimated global average risk of infection is 1%, implying approximately 38 million new infections per year among the previously uninfected population . in egypt ,researchers have found evidences of tuberculosis in the egyptian mummies dating from 3000 to 2400 before christ and who reported that tb is the most important public health problem after hepatitis c , tb disease can affect any organ, but most commonly occurs in the lungs (70%-80%). pulmonary tb is the most important form of tb infection, because an infection of the lungs is highly contagious due to the mode of droplet transmission . patients with tb usually manifest diverse signs and symptoms that vary with age, sex and the associated socio-environmental as well as host factors .

Eligibility criteria:
inclusion criteria: * all pulmonary tuberculosis adult patients (age ≥ 18 years) who will attend the outpatient clinic of chest department at assiut university hospital during 2019 - 2020. exclusion criteria: * patients less than 18 ys. loss of patient follow-up . extrapulmonary tuberculosis.
long-term follow-up study of aav2haqp1 for radiation induced xerostomia

Conditions: Radiation-induced Xerostomia

Summary: this study is a long-term follow-up study for patients who have been administered aav2haqp1 in the phase 1 open-label, dose escalation study to determine the optimal dose, safety, and activity in subjects with radiation induced parotid gland hypofunction and xerostomia

this clinical trial is designed to assess the long-term safety and activity of intra-parotid administration of aav2haqp1 in subjects with radiation-induced parotid salivary hypofunction and xerostomia. after completion of their month 12 follow-up visit in study mgt016, subjects will be invited to enroll in this 4-year follow-up study during which they will be assessed for up to 60 months following study drug administration. this follow-up trial is a non-interventional study designed to collect data on longer-term safety and activity at 18, 24, 36, 48, and 60 months following study drug administration. over the course of the study, subjects will undergo physical and oral examinations; vital sign measurements; weight measurements; ae assessments; concurrent medication assessments; sample blood collection for hematology and chemistry; urinalysis; ear, nose, and throat (ent) screening for malignancy; imaging assessments (if indicated); salivary flow assessments; and questionnaire assessments.

Eligibility criteria:
inclusion criteria: 1. are willing and able to provide informed consent 2. received aav2haqp1 administered via stensen's duct to a single or both parotid glands in the prior open-label, phase 1, dose-escalation study (study mgt016) 3. are willing and able to adhere to the protocol and long-term follow-up exclusion criteria: 1. subjects unwilling or unable to meet with the requirements of the study will be excluded
collection of biological specimens and associated health information

Conditions: Cancer; Other Disease

Summary: the purpose of this study is to collect blood samples from a large number of individuals with cancer to create a database for researchers to use in future studies. researchers may use this database to discover new ways to detect and treat cancer and other diseases. future studies may use stored blood samples to discover how genes affect health and disease.


Eligibility criteria:
inclusion criteria: * are patients of participating study site clinics/clinical groups * are adults (aged 18 or older) * have an active cancer diagnosis with confirmatory pathology results indicating solid tumor and/or hematologic malignancy * participants may have other active diagnoses with confirmatory clinical results exclusion criteria: * individuals who lack the capacity to provide informed consent * individuals known to be prisoners at time of biological specimen collection
vitamin b6 aids in treating inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: patients with ibd are randomized to oral administration of vitaminb6 and placebo based on the standard treatment, exploring whether vitaminb6 can increasee the clinical remission rateand improve the treatment effect of ibd patients.

inflammatory bowel disease (ibd) is a group of chronic idiopathic inflammatory intestinal diseases, mainly including ulcerative colitis and crohn's disease, with increasing incidence in china and worldwide. the disease currently lacks a cure, with many patients experiencing relapses and requiring surgery, and an increased risk of cancer. there is substantial evidence suggesting a close relationship between body vitamin b6 levels and ibd.thus,we design this clinical trial that aims to explore whether vitaminb6 can increasee the clinical remission rateand improve the treatment effect.

Eligibility criteria:
inclusion criteria: * patients diagnosed with ibd according to the consensus on the diagnosis and treatment of inflammatory bowel disease (beijing, 2018, doi: 10.19538/j.nk2018090106); * have complete medical history data; * volunteer to participate in this clinical trial and sign the informed consent form. exclusion criteria: * patients with peripheral neuropathy; * patients with abdominal abscess, toxic megacolon, fulminant colitis, partial colectomy, or total colectomy; * patients with other autoimmune diseases, hematologic disorders, tumors, acute infections, severe liver or kidney dysfunction, severe conditions such as severe anemia, neutropenia, heart failure, organic heart disease, hepatitis b, cirrhosis, kidney disease, and psychiatric disorders; * patients who have taken vitamin b6 tablets in the past 3 months; * patients with a history of substance abuse; * pregnant or lactating women, or those planning to become pregnant within the next 6 months; * neurological disorders such as alzheimer's disease, stroke, parkinson's disease; * participation in other clinical trials in the past 6 months; * incomplete medical records (including gender, age, diagnosis, colonoscopy results, pathological diagnosis results, and other demographic data); * currently taking: levodopa, phenobarbital, phenytoin sodium.

Keywords: vitaminb6 treatment
effect of iron and vitamin e supplementation on disease activity in patients with either crohn's disease or ulcerative colitis

Conditions: Crohn's Disease; Ulcerative Colitis; Mild or Moderate Anaemia

Summary: hypothesis:in patients with ulcerative colitis and crohn's disease diagnosed with mild or moderate anaemia: 1. iron supplementation will increase disease activity and oxidative stress 2. the addition of antioxidant vitamin will reduce this detrimental effect

to maintain site/extent of disease and medication consistent among groups, the design is a double blind crossover placebo-controlled trial. 1. if mild anaemia, patients are randomized to 300 mg of ferrous fumarate or placebo for 4 weeks followed by 2 weeks of washout period after which patients will crossover the opposite treatments for another 4 weeks. 2. if moderate anaemia, patients will receive 600 mg of ferrous fumarate for 10 weeks. they are randomized to either vitamin e (800 iu) or placebo for 4 weeks followed by 2 weeks of washout period after which patients will crossover the opposite treatments for another 4 weeks

Eligibility criteria:
inclusion criteria: * \> 18 years old * diagnosed with inflammatory bowel disease (ulcerative colitis and crohn's disease) * with mild or moderate anaemia exclusion criteria: * not diagnosed with bowel obstruction * not diagnosed with short bowel syndrome * not taking iron supplement or antioxidant vitamins and minerals
the efficacy of computerized cognitive training in adults with adhd: change in adhd symptoms, executive functions and quality of life following three months of training.

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the study group of adults with adhd who will receive cognitive (executive attention) computerized training will show significant improvement in adhd symptomatology,neuropsychological measures,daily functioning and quality of life. a significant difference will be found between the study group and the control group (adults with adhd that will receive a simplified cognitive training program that does not challenge their executive functions)on the above measures.


Eligibility criteria:
inclusion criteria: * adults (age 18-60); * 9 years education; * diagnosis of adhd; * executive function deficit in daily life; * signed informed consent. exclusion criteria: * change in pharmacological treatment and/or received new treatment for adhd in the last three months; * other current serious neurological disorder (e.g. epilepsy, brain injury, neurodegenerative disease), other major current and sever psychiatric disorder (axisi); * color blindness.

Keywords: adhd executive functions quality of life
anti-calculus efficacy of a dentrifice containing sodium pyrophosphate and potassium pyrophosphate in heavy calculus formers

Conditions: ANTICALCULUS EFFICACY OF PYROPHOSPHATE IN HEAVY CALCULUS FORMERS

Summary: the purpose of this study was to determine the anti-calculus effect of dentrifice containing 5% sodium pyrophosphate and potassium pyrophosphate in a triple-mask placebo controlled randomized clinical trial.


Eligibility criteria:
inclusion criteria: 1. age group 15-30 years. 2. subjects who have not received periodontal therapy within preceding 1year. 3. heavy calculus formers with simplified calculus index score 1.5-3 . exclusion criteria: 1. age group 15-30 years. 2. subjects who have not received periodontal therapy within preceding 1year. 3. heavy calculus formers with simplified calculus index score 1.5-3 .
the effect of probiotics (vsl) on portal hypertension

Conditions: Portal Hypertension

Summary: the investigators will address the hypothesis that portal hypertension is mediated in part by bacterial or endotoxin translocation and the production of inflammatory mediators (tumor necrosis factor-α (tnfα), etc.). the investigators hypothesize that food supplementation with the probiotic product vsl#3 in patients with child pugh b/c cirrhosis will have a beneficial effect on in portal pressure (as measured by the hvpg) by reducing inflammatory mediators and improving systemic and splanchnic hemodynamics.

we have recently completed an open-label uncontrolled trial of the probiotic vsl#3 in 8 patients with compensated cirrhosis and evidence of portal hypertension (vip study) to determine whether this agent would have beneficial effects in portal pressure reduction (unpublished data tandon, p. et al.). the open label design and the inclusion of compensated (child pugh a) cirrhotic patients in this initial study were chosen to confirm the safety and tolerance of vsl#3 and the safety of the portal pressure measurements at our center. no changes of physical status occured. there was a non-significant reduction in portal pressure from 19.7 to 18.1 mm hg after 2 months of vsl#3 supplementation. furthermore, there was a significant reduction in the serum aldosterone level (p=0.03). il-8 levels were reduced in 4/6 patients analyzed to date. these results suggest that vsl#3 results in cytokine reduction and an improvement in the effective circulating volume even in these well-compensated cirrhotic patients. the comparison of the rest of the pro-inflammatory mediators and stool microflora is still being analyzed. the data in our initial study is very promising. as our patients were compensated cirrhotics with normal intestinal permeability and only mild baseline perturbations in hepatic function parameters (inr, bilirubin, albumin) and neurohormonal markers (aldosterone, renin), it is not surprising that a reduction in portal pressure was not identified. consistent with previous studies however, these local results confirm the safety and tolerance of both vsl#3 as well as portal pressure measurements in cirrhotic patients (20,24,25).

Eligibility criteria:
inclusion criteria: * age 18-80 * cirrhosis * childs-pugh class b/c exclusion criteria: * bacterial infection * grade 3-4 hepatic encephalopathy * gi bleeding in the past 2 weeks * hepatocellular carcinoma beyond the milan criteria * transjugular intrahepatic portosystemic shunt (tips), surgical shunt * portal vein thrombosis * antibiotics in the past 2 weeks * myocardial infarction, stroke or life-threatening arrhythmia within the last 6 months * active alcohol or illicit drug use * failure to consent to the study

Keywords: portal hypertension portal pressure measurement vsl3 cirrhosis end stage liver disease probiotics
multi-omics study of tongue coating in malignant tumors of digestive tract

Conditions: Malignant Tumors of Digestive Tract

Summary: this is a prospective, multi-center, observational cohort study and seeks to enroll 20000 patients with one malignant tumor of digestive tract or healthy individual. this study collected tongue coating samples non-invasively and analyzed the tongue coating metaproteomics, metagenomics and metabolomics profiles of patients with gastrointestinal malignancies. the performance characteristics(sensitivity and specificity) of tongue coating morphology, metaproteomics, metagenomics and metabolomics tests for detection of gastrointestinal malignancies are evaluated in comparison to pathology.


Eligibility criteria:
inclusion criteria: 18≤age≤80. histologically or cytologically confirmed malignant tumor. no prior chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor treatment for malignant tumor. subject volunteers to join the study, signs informed consent, has good compliance and can cooperate with follow-up. exclusion criteria: two or more kinds of malignant tumors at the same time. malignant tumor that has been treated by chemotherapy, radiotherapy, biotherapy, immunotherapy or other anti-tumor therapy. subjects who had other factors that might force them to terminate the research ahead of time, such as the development of other severe disease (including mental disease) that required combined treatment, seriously abnormal laboratory examination value, and family or social factors that might affect the subject safety or experimental data collection, as judged by the researchers.

Keywords: tongue coating digestive tract malignant tumors multi-omics analysis
endoscopic thyroidectomy versus open thyroidectomy for papillary thyroid carcinoma

Conditions: Thyroid Cancer

Summary: recently, endoscopic thyroidectomy using gasless unilateral transaxillary approach has been proven feasible and safe in several chinese medical centers. this study is aimed to compare multi-institutional chinese outcomes of endoscopic thyroidectomy using gasless unilateral transaxillary approach and conventional open surgery.

most patients with thyroid tumors are effectively treated surgically by practitioners experienced in the techniques of thyroidectomy. many patients, especially women, undergoing thyroid surgery are concerned about the postoperative cosmetic appearance of the neck. endoscopic thyroidectomy using gasless unilateral transaxillary approach which can hide the operative scar was associated with a higher degree of patient cosmetic satisfaction. recently, endoscopic thyroidectomy using gasless unilateral transaxillary approach has been proven feasible and safe in several chinese medical centers. in this study, we designed a prospective study comparing multi-institutional chinese outcomes of endoscopic thyroidectomy using gasless unilateral transaxillary approach and conventional open surgery.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * the pathological type is papillary thyroid carcinoma; * tumor diameter \<2 cm； * no extraglandular invasion, or minimal extrathyroidal extension invading only anterior thyroid capsule or sternothyoid muscle； * cn0 or cn+ without fusion and fixation of metastatic lymph nodes； * no obvious contraindication for thyroidectomy ; * good comply with the research visit plan and other program requirements; * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * patients with severe systemic diseases who can not tolerate general anesthesia or routine surgical posture; * previous history of neck surgery, radiotherapy or thermal ablation; * hyperthyroidism and substernal goiter; * dedifferentiated thyroid carcinoma； * accompanied with severe thyroiditis.

Keywords: thyroid cancer endoscopic surgery open surgery radical thyroidectomy
effect of 2-week nightly moderate hypoxia on glucose tolerance in individuals with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to determine if 2 weeks of nightly exposure (7-12 hours per night) to moderate hypoxia (\~2,400 meters or 7,500 feet) improves glucose metabolism in people with type 2 diabetes.

exposure to hypoxia has been advocated as a possible therapeutic aid against obesity. indeed, our laboratory has provided the first evidence that intermittent, nightly exposure to moderate hypoxia is beneficial in improving insulin sensitivity in healthy obese patients and, therefore, lowers the risk of developing type 2 diabetes. benefits included reduced fasting glucose levels and improved whole-body (skeletal muscle) and hepatic insulin sensitivity. whether such intermittent hypoxia improves glucose metabolism in people with type 2 diabetes is unknown.

Eligibility criteria:
inclusion criteria: * aged 20-65 yrs * body mass index (bmi) \< 55 kg/m2 * body weight 450 lbs or less (to accommodate body composition assessment) * have either been diagnosed with type 2 diabetes, or fasting blood glucose between 125 and 200 mg/dl, or have a hemoglobin a1c ≥ 6.5% * non-smokers * weight stable over the previous 3 months (\<3 kg fluctuation) * known diagnosis of sleep apnea and ownership of a continuous positive airway pressure (c-pap) device that must be worn throughout the nights spent in the tent * if no known presence of sleep apnea, be willing to spend one night in a sleep laboratory (louisiana sleep foundation) to assess presence of sleep apnea exclusion criteria: * diagnosed with t2dm ≥ 15 years ago * pregnant women * current insulin treatment * treatment with sulfonylureas or glitinides * treatment with a glp-1 agonist * any other diabetes medication other than an oral agent is exclusionary unless otherwise cleared by medical investigator. * chronic obstructive pulmonary disease (copd) * congestive heart failure * prior severe cardiovascular events such as stroke or myocardial infarction * if treated for t2dm with other oral agent, no change in the treatment for 1 month before the study and the duration of the study * previously known diagnosis of sleep apnea without ownership of a continuous positive airway pressure (c-pap) device or agreement to use owned cpap device during the nights spent in the tent * presence of sleep apnea following a positive home sleep test (hst), or have unsafe oxyhemoglobin saturation levels (less than 78%) during a one night sleep monitoring assessment conducted at the louisiana sleep foundation without ownership of a continuous positive airway pressure (c-pap) device or agreement to use owned c-pap device during the nights spent in the tent * history of high altitude sickness * history of altitude sickness * does not have access to a bed or sleeping surface equivalent to or smaller than a queen size mattress
same-day cervical preparation before dilation and evacuation

Conditions: Cervical Dilation Prior to Dilation and Evacuation

Summary: the purpose of this randomized trial is to compare same-day cervical preparation using dilapan-s™ plus buccal misoprostol to overnight cervical preparation using dilapan-s™ before d\&e at 16.0 to 20.0 weeks. primary objective: to compare d\&e operative time. we hypothesize that same-day dilapan-s™ plus buccal misoprostol is non-inferior to overnight dilapan-s™ with respect to operative time. secondary objectives: to compare treatment groups for the following: pre-operative cervical dilation; need for mechanical dilation and ease of dilation if required; ability to complete d\&e without further cervical preparation; ease of d\&e; complications; pain; side effects; patient and provider satisfaction.


Eligibility criteria:
inclusion criteria: * 18 years of age and older * seeking pregnancy termination from 16 0/7 to 19 6/7 weeks of gestation on the day of enrollment. * eligible for pregnancy termination at ppnyc * able to give informed consent * english speaking exclusion criteria: * active bleeding or hemodynamically unstable at enrollment * signs of chorioamnionitis or clinical infection at enrollment * signs of spontaneous labor or cervical insufficiency at enrollment * spontaneous intrauterine fetal demise * allergy to dilapan-s™ or misoprostol